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ABSTRACT 
 
This cross-sectional study examined potential differences in concentration of 
Toll-like receptor 3 (TLR3) in serum and citric acid-stimulated saliva from patients with 
Sjögren’s Syndrome (SS) and healthy age-, sex-, and periodontal disease- matched 
control patients. Salivation was stimulated with 5 ml of 2% citric acid, and whole saliva 
samples were collected. Full-mouth clinical periodontal measurements were recorded 
from 21 SS patients and 22 unaffected control patients. Saliva and plasma TLR3 
concentrations were determined by enzyme-linked immunosorbentassays (ELISA). Data 
were tested statistically as appropriate to the data distribution.  
No significant difference in clinical periodontal measurements, or serum or 
salivary TLR3 concentrations was evident between groups. Salivary flow rates were 
significantly lower (p<0.001) whereas plaque % were significantly higher (p=0.048) in 
SS patients. SS patients expressed on average 0.183 and 0.219 ng/ml TLR in saliva and 
serum, respectively, while healthy control patients expressed on average 0.299 and 0.188 
ng/ml TLR in saliva and serum, respectively. These differences were not significantly 
different (p<0.05). This is the first detection of TLR3 in human serum or saliva as 
quantified or qualified by ELISA. 
The present findings do not support a hypothesis that a hyperinflammatory 
systemic state, as seen in SS patients, can independently raise serum or saliva TLR3 
concentration in the absence of periodontal disease in treated SS patients. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
I.1 SJÖGREN’S SYNDROME OVERVIEW 
 Sjögren’s Syndrome (SS) is a chronic, systemic autoimmune disorder. The 
course of the disease destroys salivary and lacrimal glands, and manifests diverse 
findings and symptoms, ranging from exocrinopathy to extraglandular, as well as 
pulmonary, hepatic, renal, and neurologic systemic involvement. Genetic, 
environmental, and hormonal factors may trigger SS. The precise etiology, or etiologies, 
has yet to be determined. B-lymphocyte hyper-reactivity, autoantibody production and 
T-cell lymphocytic infiltration to exocrine glands, and commonly, other organs, 
characterize the pathosis. The hallmark symptoms of SS are decreased exocrine gland 
function resulting in xerostomia and xeropthalmia, referred to collectively as ‘Sicca 
Syndrome’ 1.  
 In the United States, 2-4 million people are estimated to have SS, while only 1 
million have an established diagnosis. SS may go undiagnosed due to the varied and 
confounding range of clinical manifestations. SS has a predilection for women, with a 
female:male ratio of 9:1. Its onset is most commonly in the 4th to 6th decades of life. SS 
may be classified as either primary SS (pSS) or secondary SS (sSS). sSS is more 
common, and is defined by SS with a concomitant autoimmune disorder such as 
systemic sclerosis, rheumatoid arthritis, or systemic lupus erythematosus. Perhaps 25% 
of rheumatoid arthritis and systemic lupus erythematosus patients present histologic 
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evidence of SS 2. Approximately 60% of SS is secondary. pSS exists independently in 
the absence of other autoimmune disorders 3. Globally, epidemiologic data gathered on 
SS has shown significant variability. This variability may result from methodological 
inconsistencies between studies. Criteria for disease classification in studies differ, as do 
the methods used for quantitative testing of lacrimal and salivary gland function 4,5,6. 
Even within the same country, independent investigations have reported prevalence with 
10-fold differences 7. Collectively, the prevalence of pSS appears highest in northern 
Europe, lowest in Asia, and approximately equal in North America and continental 
Europe 8.  Prevalence ranging from 0.1-4.0% has been reported, with annual incidence 
from 3.9/100,000-5.3/100,000 8-13.  
I.2 CLINICAL SYMPTOMS 
 The hallmark symptoms of SS, xerostomia and xerophthalmia, may result in 
additional acute and chronic manifestations. Xerostomia may precede polydipsia, dental 
complications, oral candidiasis, angular cheilitis, and parotiditis. Xerophthalmia may 
precede corneal injury and recurrent ocular infection 14.   
 Respiratory, gastrointestinal and integumentary exocrine involvement is less 
common. However, this involvement may result in symptoms of nasal crusts and bleeds, 
parotid and submandibular swelling, dry throat, cough, esophageal mucosal atrophy, 
atrophic gastritis and dyspareunia. Extraglandular symptoms are not uncommon, and 
have been observed in up to 55% of SS patients 15. Systemic manifestations are more 
common in younger SS patients 16.  
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 SS patients report symptoms of chronic fatigue, low-grade fever and myalgias, 
arthralgias, and other organ involvement. Significant fatigue, which is often the chief 
complaint, occurs in half of patients with pSS 1.  
 Cutaneous manifestations of SS include xerosis, angular cheilitis, eyelid 
dermatitis, prutitus, cutaneous vasculitis (often as palpable purpura), and erythema 
annulare 17. Cutaneous rashes of SS often cannot be distinguished clinically or 
histologically from subcutaneous lupus erythematosus lesions 18.  Bernacchi et al., 
quantified cutaneous manifestations of SS, reporting that xerosis is the most frequent and 
characteristic cutaneous manifestation of pSS (56.4%) and sSS (25.8%) 19. Flat purpura 
and hypergammaglobulinemia are often concomitant, while palpable purpura is 
associated with dermal vasculitis. Dermal vasculitis is linked with SS-related 
extraglandular manifestations and lymphoma 20. In a recent study of pSS, 89 of 559 
patients (16%) presented with cutaneous involvement.  Cutaneous vasculitis was the 
most common cutaneous involvement (58%). Small vessel, leukocytoclastic vasculitis 
was predominant. Vasculitis is associated with extraglandular and immunologic SS 
features. Clinically, small vessel vasculitis presents as palpable purpura, urticaria or 
erthematosus maculopapules 20.  
 Arthritis independent of or present with arthralgia are frequently diagnosed as 
well. Following a 4.5-year observation of 102 patients with pSS, 73.5% reported 
arthralgia and 17.6% demonstrated arthritis. The ankles, metacarpal and metatarsal 
joints, shoulders and wrists were the most commonly affected joints 21.  
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 Muscle pain is common in pSS. In a study of 48 pSS patients, 44% complained 
of muscle pain, while 27% fulfilled the American College of Rheumatology criteria for 
fibromyalgia. Of the 36 muscle biopsies obtained for the study, 26 (72%) showed signs 
of inflammation. Abnormal expression of major histocompatibility complex (MHC) 
class I, MHC class II and MAC was found in 50%, 44%, and 75% of pSS biopsies, thus 
histopathologic signs of myositis are common 22.  
 Neurological manifestations of SS are not uncommon, and are well documented. 
SS patients most commonly have a sensory neuropathy affecting the feet and lower legs. 
This neuropathy affects light touch, proprioception and vibratory sensation. 
Manifestations of peripheral neuropathy include sensory ataxic neuropathy, painful 
sensory neuropathy without sensory ataxia, multiple mononeuropathies, multiple cranial 
neuropathy, trigeminal neuropathy, autonomic neuropathy, and radiculoneuropathy 23.  
 In a study of pSS patients conducted by Scofield et al., of 12 pSS positive for 
both anti-Ro and anti-La, 8 (66.7%) had neuropathy. Among 76 of 88 pSS patients 
studied with anti-Ro or anti-La positivity, 19 (25%) had neuropathy. Overall, 
approximately 30% of pSS patients displayed a pure sensory neuropathy 24. A study 
conducted by Gono et al., observed 47% of the pSS patients participating displayed pure 
sensory neuropathy 25. However, the incidence of these observations contrasts drastically 
with those from Pavalakis et al., who observed approximately 1% displaying sensory 
neuropathy 26.  
 Although pSS incidence in patients with interstitial lung disease (ILD) is not 
significantly elevated, patients with pSS who have ILD likely have increased premature 
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mortality 27. Hypergammaglobulinemia and lymphopenia, positivity for RF, anti-La and 
anti-Ro, and impaired forced vital capacity and/or forced expiratory volume in 1 second 
values may be predictive parameters with a high specificity for detection of pSS-
associated lung disease 28.  
 Renal pathosis is a documented finding in SS 29.  Chronic tubulointerstitial 
nephritis is the predominant kidney biopsy finding in patients with renal involvement 
from pSS 30. An interstitial lymphocytic infiltrate with tubular atrophy and fibrosis is the 
most commonly reported histopathologic lesion. This lymphocytic infiltrate correlates 
with tubular dysfunction 29. Pertovaara reported that high levels of serum total gamma-
globulin, serum protein and serum beta2m were the best predictors of the development 
of distal renal tubule acidosis in pSS patients 31.  
 Common gastrointestinal symptoms include dysphagia, dysmotility and gastritis. 
Dyspepsia was reported in 23% of pSS patients 32. A Hungarian study found the 
frequency of celiac disease to be approximately 10 times higher in pSS patients than 
non-SS patients 33.  
 Jara et al., described thyroid dysfunction in SS patients, reporting that pSS was 
ten times more frequent in patients with autoimmune thyroid disease, and autoimmune 
thyroiditis was nine times more frequent in pSS. Those who suffer from pSS were most 
likely to develop hypothyroidism among any who have common autoimmune  
diseases 34.  
 Approximately 5% of SS develop lymphoproliferative disorders. B-cell 
hyperactivity explains increased prevalence of these diseases 35.The odds ratio of 
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lymphoma was 4.75 in pSS and 9.57 in sSS 36. Palpable purpura, low C4 levels, and 
mixed monoclonal cryoglobulinaemia are risk factors for the comorbidity of lymphoma 
and SS 1, 37. 
I.3 DIAGNOSIS OF  SJÖGREN’S SYNDROME 
 Diagnosis of SS is multifaceted and difficult. To date, no one sign, symptom, or 
lab value is exclusive to SS. Standardization of diagnostic criteria of the disease has only 
recently developed. The two prevailing diagnostic criteria are the European classification 
criteria and the European classification criteria as revised by the American European 
Consensus (AECC) group 38, 39. 
 The hallmark symptoms of xerostomia and xeropthalmia must be present in 
addition to laboratory findings. The revised AECC criteria are reportedly more specific, 
however less sensitive than the European classification criteria in the diagnosis of pSS. 
The specificity and sensitivity of the European classification criteria are 75% and 65.7%, 
respectively, compared to 97.2% and 48.6%, of the AECC. When applied to sSS, 
specificity of the two classification systems is equal, and the European classification 
criteria remain more sensitive (70.6% versus 64.7%) 40. 
 If SS is suspected, other symptomatic etiologies causing xerostomia and 
xerophthalmia must be considered in a differential diagnosis. Appropriate exclusion 
criteria including use of anticholingergic drugs, hepatitis C and HIV infection, 
lymphoma, sarcoidosis, graft-versus host disease and previous head and/or neck 
radiation. Further complicating diagnosis, ‘sicca syndrome’ symptoms may be mimicked 
by amyloidosis, trauma, and scaring. Chronic blepharitis or conjunctivitis, neurogenic 
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impairment of eyelid function or lacrimal gland dysfunction may result in 
xerophthalmia. Diabetes mellitus, hypercalcaemia and multiple medications may cause 
xerostomia 14. 
 Thus, an unequivocal diagnosis of SS requires subjective patient report as well as 
multiple objective parameters. Non-organ specific antigens including immunoglobulins, 
alpha-fodrin 41, nuclear antigens, and extractable nuclear and cytoplasmic antigens are 
targeted by autoantibodies 14. Borg et al., reported anti-Ro/SS-A and/or anti-La/SS-B in 
80%, immunoglobulin M-Rheumatoid factor (IgM-RF) in 68%, and anti-nuclear 
antibody (ANA) in 77% of 65 SS studied 42. Anti-Ro/SS-A and anti-La/SS-B are 
included in the diagnostic criteria for SS. Anti-Ro/SS-A is more commonly found in SS, 
however, anti-La/SS-B is considered more specific. Once a definitive diagnosis of SS is 
made, anti-Ro/SS-A and anti-La/SS-B may be used to monitor disease activity and 
progression. These antibodies correlate with disease severity and activity. Anti-Ro/SS-A 
and anti-La/SS-B may serve as predictors for future SS in the absence of symptoms as 
well 43. However, absence of anti-Ro/SS-A and/or anti-La/SS-B does not preclude a 
diagnosis of SS.  
I.4 IMMUNE DYSREGULATION IN SJÖGREN’S SYNDROME 
 Both innate and adaptive immune system alteration has been documented in SS. 
Though the factor initiating salivary gland destruction remains to be discovered, it is 
speculated that viral infection serves as an impetus. Viral infection may be a font of 
antigenic ligands to Toll-like receptors (TLRs), located on dendritic and epithelial cells 
of the salivary glands. Viral ligands binding to TLRs initiate an immune cascade. TLRs 
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are activated, presenting MHC class 2 molecules and secreting cytokines and 
chemokines including Type-1 IFN 14. 
 The involvement of Type-1 IFN in the development and progression of SS has 
been thoroughly investigated. Microarray data from minor salivary glands, peripheral 
blood mononuclear cells, and whole and peripheral blood CD14+ monocytes revealed 
that Type-1 IFN inducible pro-inflammatory and anti-viral genes were among the mostly 
up-regulated genes in SS patients. Over-expression of Type-1 IFN-inducible genes also 
correlated with the presence of antibodies to Ro/SSA and La/SSB antigens. Notably, 
IFN-induced genes include B-cell activating factor (BAFF) 44. Plasmacytoid dendritic 
cells, which have been identified in the salivary glands of SS patients, produce Type 1-
IFN. IFN-inducible genes IFITM1 and BAFF were highly expressed in those glands as  
well 45. 
 BAFF levels are significantly increased in SS. This over-expression is implicated 
in B-cell tolerance breakdown in SS. Aberrant B-cell distribution, hyperactivity and 
autoantibody production are abnormalities associated with over-expression. Monocytes 
and epithelial cells produce BAFF. BAFF stimulates B-cell survival 46. Seropositivity for 
anti-Ro/SS-A or anti-La/SS-B has been correlated with increased BAFF levels 47. 
Increased BAFF has also been correlated to know lymphoproliferative complications in 
SS including B-cell lymphoma. Other cytokines reputed to be involved in SS 
pathogenesis include interleukin(IL)–6, IL-12, IL-17 and IL-21. An in vivo animal 
model has demonstrated IL-12 induced salivary gland damage 14. 
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 Secretion of cytokines following innate immune system activation precipitates 
migration of T and B lymphocytes from serum to the salivary gland parenchyma. 
Lymphocyte invasion starts at the periductal area and spreads as pan-lobular invasion. 
CD8 T-cells are present, though CD4 T-cells predominate. Antibody-secreting B-cells 
comprise a minority of infiltrating cells 48. T-cell activation in SS has been highly 
associated with increased IL-6. Increased IL-6 may increase Th-17, which belongs to a 
pro-inflammatory subset of CD4 T cells, in salivary glands. Th17 cells secrete IL-17, a 
pro-inflammatory cytokine implicated in multiple autoimmune disorders 49. The 
invading lymphocytes are then activated by epithelial and dendritic cells, which act as 
antigen presenting cells within the glands. Ro/SS-A and La/SS-B, alpha and beta fodrin 
and cholinergic muscarinic receptor antigens constitute the specific antigens presented in 
SS 14. 
 An alternative mechanism of salivary gland pathogenesis is a proposed immune-
mediated neurotransmission alteration. Dawson, et al., demonstrated in vitro that 
immunoglobulin G (IgG) from pSS patients contains putative anti-muscarinic antibodies 
directed against muscarinic M3 receptors. Normally, binding of acetylcholine to M3 
parasympathetic receptors would result in salivary production. However, the anti-
muscarinic IgG antibodies inhibited production 50. Damage to muscarinic receptors by 
autoantibodies may precipitate and precede exocrinopathy. Parasympathetic nerves 
innervate the salivary glands. Therefore, damage to M3 muscarinic receptor by 
autoantibodies would alter acetylcholine binding from parasympathetic nerves. Indeed, 
antibodies to M3 have been documented in SS patients 41. 
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 The spatial location of water channel proteins, including aquaporins (AQP), on 
epithelial cells may affect salivary secretion as well. Normally located on the apical 
membrane of acinar cells, an AQP5 isoform was located on the basolateral membrane in 
pSS patients. In these patients, treatment with anti-tumor necrosis factor (TNF)-alpha 
antibody repositioned AQP5 to its normal apical position 51, 52. This positional 
restoration was accompanied by improvement of salivary flow. 
 Anti-Ro/SS-A and anti-La/SS-B  have been and continue to be an essential 
component of SS. Ro/SS-A antigens include Ro52 and Ro60. These antigens were once 
considered as a uniform, coupled system. Chan, et al., demonstrated that they are 
distinct, encoded by different genes 53. Ro60 is a 60 kDa protein component of a small 
cytoplasmic ribonucleoprotein complex 54. Ro52 is a 52 kDa RING/Bbox/coiled-coil 
(RBCC) tripartite motif protein (TRIM), and an over-expressed ubiquitin-ligase in 
peripheral blood mononuclear cells in SS and systemic lupus erythematosus patients 55, 
56. The anti-Ro/SSA proteins negatively regulate cytokine production induced by the 
IFN-gamma pathway by functioning as an E3 ligase 57. La antigen is a 47 kDa protein 
involved in RNA polymerase III transcription, tRNA biogenesis, mRNA stabilization, 
and translational regulation 58. Accurate detection of these antibodies remains difficult.  
If Ro/SS-A samples contain both Ro52 and Ro60 and a classical SS-A ELISA is used for 
quantification, up to 20% of Ro52 or Ro60 positive samples may remain undetected 57. 
 Research by Ramos-Casals et al., noted that patients with a young onset of pSS, 
defined as younger than 35 years old, presented a higher prevalence of anti-Ro/SS-A 
antibodies than an patients with onset after 35 (70% vs 28%) 59. When compared to 
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younger pSS patients, pSS patients with disease onset occurring after 70 years old, the 
prevalence of anti-Ro/SS-A or anti-La/SS-B was similar 60. When pSS is compared by 
gender, some studies report men may have a lower anti-Ro/SS-A and/or anti-La/SS-B 
antibody frequency 61, 62 . However, this is not a unanimous observation 63. 
 The literature is more united regarding antibody presence and extraglandular 
clinical course. Patients possessing these antibodies display parotiditis and extra-
glandular complications more frequently than those who do not 64-67. Locht et al., 
concluded that anti-La/SS-B are strong predictors of internal organ affection in pSS, 
whereas anti-Ro/SS-A are not associated with complications of the kidneys, lungs or 
liver among pSS patients 66. 
 The relationship between antibodies and lymphoma is not yet understood. 
Davidson et al., reported that 3 of 100 pSS patients studied developed non-Hodgkin 
lymphoma during a 10 year observation period 68. All 3 were anti-Ro/SS-A and anti-
La/SS-B positive. Conversely, an Italian study found that of pSS patients with non-
Hodgkin’s lymphoma, 37% were anti-Ro/SS-A and 50% anti-La/SS-B positive 67. 
 Toker et al., documented anti-Ro/SS-A and anti-La/SS-B autoantibodies in the 
lacrimal tears of pSS, and a correlation of these autoantibodies with rose Bengal staining 
scores, Schirmer I test score, and xeropthalmia symptoms 69. Markusse et al., echoed 
Toker’s report of a correlation, and also reported a correlation between anti-Ro/SS-A 
and an abnormal sialogram 70. Tsuzaka et al., observed severe parotid swelling and 
salivary gland dysfunction among pSS patients with serological abnormalities with anti-
Ro/SSA and with or without anti-La/SS-B 71. Among pSS patients, the degree of 
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infiltration in the labial salivary gland tissue was significantly greater in patients with 
anti-Ro/SS-A plus anti-La/SS-B antibodies in their sera than in patients with anti-Ro/SS-
A antibodies alone (p< 0.05) 72. 
 Serological abnormalities including hypergammaglobulinemia 73, 74, 
hypocomplementemia 75, 76, high rheumatoid factor, high serum levels of IgG and IgA 77, 
78, mixed monoclonal IgM cryoglobulins 79, and positive ANA80 titers are well 
established associations with pSS and seropositivity for anti-Ro/SS-A and anti-La/SS-B.  
I.5 PERIODONTAL DISEASE AND SJÖGRENS SYNDROME 
 The relationship between SS and periodontal disease is the subject of 
investigation and debate. Clinical, microbiological, and biochemical studies have been 
conducted to elucidate whether or not a relationship exists, and, should it exist, what its 
nature is. A viral etiology may be shared by both periodontal disease and SS. Evidence 
of this will be addressed following the presentation of literature which investigated the 
simultaneous incidence, prevalence, and disease progression of periodontal disease and 
SS. 
 Clinical studies comparing SS patients to healthy controls have reported varied 
findings. Antoniazzi et al., observed that pSS and sSS patients, as diagnosed by the 
European Community criteria for SS, had significantly higher mean plaque index (PI), 
gingival index (GI), probing depth (PD), clinical attachment level (CAL), and bleeding 
on probing (BOP) than SS-free controls. Only GI remained significantly higher in 
patients with SS once adjustment for plaque was made. Subjects with pSS showed lower 
gingival crevicular fluid (GCF) IL-1beta levels compared to SS-free controls 81. Najera 
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et al., qualified SS using the same criteria as Antoniazzi and compared the periodontal 
status of SS patients to SS-free controls. SS patients had significantly higher PI, 
decayed/missing/filled teeth, increased alveolar bone loss, CAL and cement-enamel 
junction to-bone crest loss. Najera did not find any significant difference in the number 
of cases of “established periodontitis” between SS and SS-free subjects. However, he 
concluded that odds ratio analysis suggested SS patients are at 2.2 higher risk of 
periodontal disease than SS-free 82. Though which criteria used for SS diagnosis was not 
disclosed, Celenligil et al., recorded clinical periodontal parameters as well as serum IgG 
antibody levels of a panel of 13 oral microorganisms in pSS and sSS patients, as well as 
healthy controls. Significantly higher PI, BOP, PD, and PI scores were observed in SS 
patients. SS patients also exhibited significantly elevated antibody levels to 
Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. The authors thus 
purposed that SS may affect bacterial colonization in plaque and contribute to increased 
periodontal disease 83.  
 Conversely, Kuru et al., reported that the occurrence, severity and extent of 
periodontal lesions were not significantly different between pSS, sSS and SS-free 
patients. PI, GI, BOP, PD, CAL, as well as other parameters were essentially equivalent. 
Furthermore, microbiological assay of subgingival dental plaque samples by 
Periocheck® and polymerase chain reaction (PCR) analysis showed no difference in 
frequency of periodontal pathogens. The authors posited that these results neither 
supported a SS-specific clinical and microbiological periodontal status requiring special 
periodontal care, nor that the periodontal status of patients with SS was significantly 
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different from healthy SS-free control 84. Schiødt et al., concluded that pSS is not 
associated with increased risk of periodontal disease. Fifty-seven pSS patients and 80 
SS-free age-matched controls were evaluated clinically. pSS was qualified using the 
Copenhagen criteria. The Danish study found no significant difference in any clinical 
periodontal parameter 85. Using the American-European Consensus criteria for pSS, 20 
pSS patients were compared to 20 age-matched healthy controls. As expected, salivary 
flow rates were lower among pSS patients. Excluding a slightly higher GI, the 
periodontal parameters measure did not differ significantly between groups Furthermore, 
PI, GI, and PD were not correlated to salivary flow rates 86. An earlier study by Pedersen 
qualifying pSS using the European consensus criteria found similar results 87.  Boutsi et 
al., found no difference in the clinical periodontal parameters between pSS/sSS patients, 
SS-free patients with other immune diseases and SS-free/immune disease free patients 
with subjective xerostomia 88. When comparing the periodontal parameters of pSS 
patient to SS-free/xerostomic and SS-free/periodontal disease patients, Pers et al., 
reported that despite a significantly lower PI in pSS patients, the three groups did not 
differ with respect to modified GI, papillary bleeding, or PD. The PI of pSS patients did 
not correlate with other periodontal variables. Compared to SS-free groups, pSS patients 
did exhibit a significantly higher salivary level of BAFF 89. Jorkjend et al., found that SS 
patients stratified by salivary output, as compared to SS-free xerostomic patients 
stratified by salivary output, showed no statistically significant differences in periodontal 
status as measured by attachment loss, leading the authors to suggest that SS patients do 
not have an increased risk for developing periodontitis 90. 
 15 
 
 A small clinical study by Tervahartiala et al., assessed the periodontal status and 
collagenase, elastase and gelatinase in gingival crevicular fluid in patients with SS, 
periodontal disease, and healthy SS-free/periodontal disease-free controls. Of note, SS 
was diagnosed using the Copenhagen criteria. The collagenase and elastase activity was 
significantly lower in SS patients and controls than SS-free patients with periodontitis. 
Gelatinase profiles were similar among all groups. Though a visible plaque index, 
gingival bleeding index, and pocket depth were reportedly assessed for each patient, the 
results were not reported. The author commented that, “With one exception, the clinical 
status in SS was comparable to that found in control subjects with healthy periodontium 
and oral mucosa, and unlike that you in adult patients with periodontitis” 91. Ravald et 
al., investigated dental caries, periodontal parameters, stimulated and unstimulated saliva 
in patients with pSS and healthy controls. All periodontal parameters measured, 
including PD, furcation involvement, bleeding on probing and PI did not differ 
significantly, which Ravald notes is in agreement with Tervahartiala’s findings as well 
as Tseng’s findings 92.Tseng determined the periodontal status of 14 SS and 14 SS-free 
age-matched female. PI, GI, bleeding on probing, calculus, CAL and PD were recorded 
on 7 test teeth. There were no statistically significant differences between the SS and 
control groups. Tseng concluded that Sjögren's syndrome has no observable influence 
upon the indices measured in evaluating periodontal disease 93. In a study investigating 
periodontal status and sulcular Candida albicans colonization in pSS patients, pSS 
patients had significantly great CAL as compared to SS-free controls. PD, GI and PI 
were not significantly different. The increased attachment loss in pSS patients was not 
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attributed to an increase in colonization of the gingival sulci by Candida albicans 
organisms 94. 
 Alteration of vascular anatomy in patients with SS is documented by studies 
utilizing nail fold capillaroscopy 95. Whether the digital alterations are pathognomonic of 
SS or present in a subset of patients is debated 96. Other authors explain that patients 
with SS have a normal morphologic pattern of capillaries, but that there is an abnormal 
macrovascular and microvascular reactivity 97, 98, 99. The morphology of oral vasculature 
has been investigated as well. Scardina et al., compared the capillaroscopic 
microcirculation pattern of the interdental papilla of patients with SS and healthy 
controls. The capillaries of SS patients exhibited significantly greater apical, afferent and 
efferent capillary diameter, capillary density and capillary tortuosity, creating a 
pathognomonic periodontal SS vascular morphology. Only the length of the visible 
capillary loops was not significantly different between SS and controls. This forms a 
cobweb conformation rather than a more typical punctuated pattern 100. A similarly 
distinct pattern of microvascular alteration was described when capillarosocopy was 
applied to the mucosa of the lower lip corresponding to the frenulum 101. 
I.6 SJÖGREN’S SYNDROME AND VIRAL INFECTION 
 A viral pathogenesis of SS has been proposed. Salivary gland immune response 
in SS is characterized by IFN signature. This signature includes over-expression of IFN-
inducible genes including interferon-stimulated transcription factor-3-gamma (ISF3G) 
and IFN-induced transmembrane proteins (IFITM1). Hjelmervik et al., used a 16K 
complementary DNA microarray to generate gene expression profiles in minor salivary 
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glands (MSGs) obtained from 10 patients with primary SS (pSS) and 10 control subjects. 
Quantitative reverse transcriptase-PCR validated the results. The authors found a distinct 
difference in gene expression levels of MSGs. Among the differences between pSS and 
controls was the increased expression of numerous type-1 IFN genes related to virus 
infection as compared to controls 102. Work by Gottenberg et al., supported Hjelmervik’s 
findings 103. 
 The cause of cellular activation and the chronic inflammatory response that 
targets epithelial cells in SS is not known. There is evidence that a persistent viral 
infection may cause pSS. Work by Fox et al., drew attention to Epstein-Barr virus (EBV) 
as a possible initiation factor in pSS pathogenesis. Salivary gland biopsies were 
performed on 14 pSS patients, and salivary samples taken from 20 pSS patients. In 8 of 
14 biopsies, cytoplasmic staining of ductal and/or acinar epithelial cells with monoclonal 
antibody against the EBV-encoded early “D” antigen was noted. This antibody was non-
reactive with any other tissues obtained from pSS. The absence of late structural 
antigens like gp200/350 negate a lytic EBV infection. Eight of 20 salivary samples from 
pSS contained detectable EBV. EBV was not detectable in any pSS-free participants. 
Furthermore, presence of EBV was associated with clinically more severe SS. The 
authors hypothesized that EBV-associated antigens in the salivary gland may serve as a 
target for immune recognition and lymphoproliferation by T- and/or B- cells, causing 
infiltration and destruction of salivary glands 104. Saito et al., extracted DNA from 
peripheral blood mononuclear cells (PBMC) and salivary gland biopsy tissue from SS 
and SS-free controls. Following PCR, the frequency of SS salivary glands containing 
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EBV DNA was 78%. 18% of SS PBMC contained EBV DNA. SS-free controls 
expressed 13% frequency in salivary glands and 6% in PBMC 105. In situ hybridization 
and PCR was used by Mariette et al., to detect EBV DNA in salivary gland biopsy 
specimens from pSS and sSS patients as well as SS-free controls. In situ hybridization 
revealed EBV DNA in the epithelial cells of biopsy specimens in 50% of pSS, none in 
sSS, and 8% of SS-free controls. 86% of pSS, 60% of sSS and 29% of SS-free patients 
were EBV DNA positive as detected by PCR. A statistically significant increase in EBV 
DNA of pSS as compared to SS-free controls was revealed by both detection techniques 
106. The association of EBV with SS was further supported by the results of Wen et al., 
who detected EBV genomes and their products in epithelial cells and lymphocytes in 
over half of the salivary glands of SS patients studied. EBV genome was not present in 
any SS-free control specimens 107. 
 The detection of EBV DNA in primarily or exclusively SS salivary glands has 
not been observed by all studies. Maitland et al., examined labial minor salivary gland 
biopsies for EBV and human cytomegalovirus (HCMV) DNA by PCR in patients with 
sSS and SS-free non-specific sialadenitis patients. No significant difference between the 
detection of EBV or HCMV in salivary gland biopsies from sSS patients or SS-free 
patients. Of note, the SS patients in the study conducted by Fox were not specified as 
pSS or sSS. Furthermore, the controls were disease-free and without sialadenitis 108. 
Venables et al., examined 12 minor and labial salivary gland biopsies from 12 pSS and 
10 SS-free controls for EBV DNA. Utilizing in-situ hybridization and 
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immunofluorescence, DNA was identified in 2 of 12 pSS patients and 6 of 10 controls. 
Of the 6 control biopsies, 5 were without inflammation or Class II expression 109. 
 While EBV has been identified in SS in some studies, its existence in either a 
lytic or latent state is debated. Late structural protein gp320/330 was not expressed in 
some studies 110, 107. Positive staining in epithelial cells and scattered B-lymphocytes for 
the protein product of BamHI fragment Z, ZEBRA, were observed in other studies. 
ZEBRA is believed to convert EBV from a latent to a lytic state 109, 110. 
 When the evidence of EBV as a causative agent in SS is weighed, it is, as a body, 
inconclusive. The unique role of EBV in SS, if any, remains to be clearly defined. Other 
viruses have been considered as pathogenic agents as well. 
 Human T lymphotropic virus type 1 (HTLV-1), human immunodeficiency virus 
(HIV), intracisternal A type particles, and human retrovirus 5 (HRV-5) have been 
associated with pSS. An infectiously acquired genome, HRV-5, was discovered by 
reverse transcriptase PCR from the salivary gland tissue of a SS patient. The 932-bp 
retrovirus sequence is related to type B and D retroviruses 111. Following the discovery 
of HRV-5 in a SS-positive biopsy, Rigby et al., examined 93 minor salivary gland tissue 
samples and found no association of the virus with SS 112. HRV-5 was later quantified in 
synovial sample for arthritic joints, blood samples from rheumatoid arthritis and 
systemic lupus erythematosus 113. Even if HRV-5 is not itself directly or uniquely 
involved in the pathogenesis of SS, retroviruses may cause proliferation of endogenous 
and defective retroviral RNAs 114. 
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 A-type retroviruses were described as those with a characteristic intracellular 
morphology of a thick shell with an electron-lucent, hollow center. These characteristic 
structures are now recognized to be an intermediate, immature viral capsid transitioning 
to more mature structures. ‘A-type retrovirus’ is still used to describe endogenous non-
infectious retrotransposon structures now referred to as intracisternal type A particles 
(IAPs). IAPs conduct the assembly of morphologically-immature virus-like particles. 
These particles are not released efficiently extracellularly, budding into the lumen of the 
endoplasmic reticular cisterns 115. Garry et al., observed IAPs in T-lymphoblastoid cell 
cultures treated with tissue homogenates from pSS salivary glands. pSS homogenate 
treated cultured cells were then examined by transmission electron microscopy and 
determined to express viral particles similar to HIV. These viral particles could then 
possibly serve as an antigenic stimulus for production of glycosaminoglycan (Gag)-
reactive antibodies in sera from patients suffering from autoimmune disorders 116. Using 
an immunoblotting assay, PCR, reverse transcriptase activity assay, and transmission 
electron microsocopy, Yamano et al., also observed unknown IAPs in labial salivary 
glands and peripheral blood mononuclear cells of pSS 117. Sanders reported that patients 
with autoimmune disorders display antibodies against IAP proteins 118. 
 Single stranded RNA viruses have been implicated in SS as well. 
Triantafyllopoulou et al., provided evidence that pSS may be associated with 
coxsackievirus infection of minor salivary gland epithelial cells and local lymphocytic 
infiltrates. Coxsackieviruses are single-stranded, non-enveloped family picornaviridae 
RNA viruses. The authors applied a differential display protocol and semi-nested reverse 
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trascriptase-PCR to MSG RNA samples from pSS, sSS, SS-free/autoimmune disease-
positive, and SS-free/healthy controls.11 of 12 pSS, 1 of 13 sSS, and no controls were 
positive for the presence of coxsackievirus genome or the main antigenic capsid protein 
VP1. The amplification products were identical to the coxsackieviral serotypes B4 and 
A13 119. However, Triantafyllopoulou’s et al., findings could not be duplicated by 
Gottenberg et al., 103. 
 Triantafyllopoulou et al., posited the continued study of coxsackievirues as 
possible pathogens in pSS. He argued that significant evidence exists that 
coxsackieviruses establish persistent non-cytolytic infections in vitro, resulting in 
autoimmune induction as has been observed in type 1 diabetes and autoimmune dilated 
cardiomyopathy 120. Next, Triantafyllopoulou argued that host-cell protein interaction 
with coxsackievirus may be related to autoimmunity induction. Translocation of the La 
protein from the nucleus to the cytoplasm has been shown following enterovirus 
cleavage of the La protein 121. This translocation is considered essential for the 
recognition of La as an autoantigen. Finally, B-cell polyclonal activation may be 
triggered by persistent noncytopathic RNA viral infection of epithelial cells, as has been 
demonstrated by HCMV infection of pancreatic islet cells and the observed polyclonal 
hyper-gammaglobulinema and autoantibody production 122. 
I.7 PERIODONTAL DISEASE AND VIRAL INFECTION 
 The proposed causes of periodontal disease are many. The body of literature on 
periodontal pathology has focused primarily on bacterial etiology. However, 
investigation of viruses in periodontal disease suggests concomitant viral infection. 
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EBV, HCMV, and HSV as well as other common viruses have been the focus of several 
studies as possible etiologic agents. These studies have collected virus-positive samples 
from subgingival plaque samples, gingival crevicular fluid, tissue biopsies, as well as 
serum and saliva samples. International, independent scientific investigation continues to 
add evidence of a viral pathogenesis. 
 Contreras et al., investigated the frequency of HCMV, EBV-1, EBV-2, herpes 
simplex virus (HSV) and human immunodeficiency virus (HIV) by means of a nested-
PCR. Subgingival specimens were obtained by paper-point sampling from deep (7-9 
mm) sites and shallow (3-5 mm) sites. Of 27 participants, HCMV was observed in 14, 
EBV-1 in 10, HSV in 7, EBV-2 in 6 and HIV in 1. 89% of participants were positive for 
at least one virus in deep sites. By comparison, 56% of shallow sites were positive. Also, 
viral co-infection was four times as common in deep sites 123. When classified as 
periodontally healthy, chronic periodontitis, and aggressive periodontitis, Das et al., 
found that HSV-1 and EBV are significantly associated with chronic and aggressive 
periodontitis, and that when present in aggressive periodontitis, HSV-1 was associated 
with sites with increased probing depth and CAL 124. Among the Japanese population 
studied by Kato et al., EBV DNA was found more frequently in patients with PD at least 
5 mm deep (deep sites) rather than PD no more than 3 mm (shallow sites). Furthermore, 
EBV was present with P. gingivalis in 40% of deep sites versus 14% of shallow sites. 
Furthermore, the odds ratio of EBV DNA in patients with deeper sites was 2.36 of EBV 
DNA. This was 2.07-fold greater than those with shallow sites. Collectively, Kato et al., 
posits that EBV DNA may be a pathogenic factor in chronic periodontitis 125. 
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 Viral pathogens have been detected in the periodontal anatomy as well. Madinier 
et al., used a Southern blot with 32P-radiolabeled DNA probes to screen intra- and extra- 
oral tissue samples for EBV DNA. EBV DNA was present in the interproximal papilla 
samples obtained. Only 1 of 20 extra-periodontal mucosal samples contained 
homologous EBV DNA. These periodontal status of the teeth from which the 
surrounding tissue samples were obtained was not recorded 126. Vincent-Bugnas et al., 
reported, for the first time in the literature, EBV-infected junctional and sulcular 
epithelial cells in periodontally diseased tissue. EBV was detected not only in 
periodontally diseased sites but healthy sites as well. The level of EBV infection 
positively correlated with disease severity. Vincent-Bugnas observed that EBV-infected 
epithelial cells are typically in a latent state, as evidenced by the presence of latent 
transcripts including EBNA1, EBNA3, LMP1, and LMP2. It was also observed that 
infection of sulcular and junctional epithelium cells with EBV was associated with 
apoptotic cell death 127. The observation of viral pathogens in these structures may be 
important to better understanding periodontal regeneration. 
 Few studies have investigated how the presence of viral pathogens affects the 
outcome of periodontal therapy. Bertoldi et al., investigated whether the presence of 
herpes simplex 1 and 2 (HSV-1 and HSV-2) affected the clinical outcomes of surgical 
periodontal regeneration in isolated deep intraosseous defects free of common 
periodontopathogenic bacteria. Patients diagnosed with generalized chronic periodontitis 
with no less than one deep intraosseous defect were selected. Following non-surgical 
therapy, and whole mouth surgical therapy everywhere but the deepest intraosseous 
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defect, a base line examination and microbiological profile of each participant was 
completed. Only patients free of periodontogenic bacteria, including Actinobacillus 
actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythensis, 
Treponema denticola, Gusobacterium nucleatum, and Prevotella intermedia were 
included. The minimally invasive surgical technique (MIST) with application of 
Emdogain was then applied to the remaining intraosseous defect. One year following 
surgical therapy, HSV-1 and HSV-2 were quantified in the pocket tissues associated to 
the intraosseous defects. Of the 17 defects treated, 5 were positive for HSV-1. HSV-2 
was not detected in any site. CAL gain and PD reduction were significantly worse in 
patients who tested positive for HSV-1 following surgical intervention as compared to 
HSV-1 negative patients. Gingival recession was greater among HSV-1 positive patients 
as well. As the number of HSV-1 DNA copies increased, the amount of CAL gain and 
PD reduction decreased, gingival recession increased as well. HSV-1 negative patients 
gained 5.92 +/- 1.93 mm CA, while HSV-1 positive patients gained only  
0.2+/- 1.79 mm 128. 
 Some studies have explored viral DNA in salivary samples. Idesawa et al., 
observed that the stimulated whole saliva of 48.5% of patients with periodontitis was 
EBV positive. Comparatively, the saliva of 15% of healthy subjects was positive. 
Periodontitis was defined as at least two clinical probing depths greater than 4 mm. 
Significantly less BOP was observed among EBV negative periodontitis patients as 
compared to EBV positive periodontitis patients. Following initial, non-surgical 
periodontal therapy, a significant reduction in EBV positive patients, EBV levels, and 
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BOP was observed 129. Bilder et al., examined unstimulated saliva samples from chronic 
periodontitis patients, with at least 2 teeth with at least 6 mm CAL and at least 5 mm PD. 
Two periodontally healthy groups were included as well, distinguished by whether or not 
they belonged to a dental profession. Fifteen percent, 5%, and 40% of salivary samples 
from chronic periodontitis patients tested positive for HCMV, HSV-1, and EBV, 
respectively. Neither healthy group was HCMV positive. Otherwise, virus frequency 
was not significantly different among groups 130. Dawson et al., tested the hypothesis 
that salivary levels of EBV and HCMV DNA correlate with periodontal disease severity. 
Additional criteria to qualify patients as periodontally diseased included PD no less than 
5 mm, at least 3 mm CAL, and BOP. Of note, patients with salivary gland dysfunction 
were excluded. Following collection of 5 ml of unstimulated saliva, periodontal 
examinations were performed. All participants were diagnosed with moderate or severe 
periodontal disease. EBV and HCMV DNA were detected in the saliva of 81.5% and 
1.5% of patients, respectively, and in the subgingival plaque samples of 44.6% and 0.3% 
of patients, respectively. The presence of EBV in saliva did not correlate with increasing 
severity of periodontal disease, though it did increase the chance of the presence of 
subgingival plaque ten-fold 131. Sahin et al., investigated EBV and HCMV as well. In 
addition to participants with periodontal disease, Sahin included participants with 
gingivitis and edentulous patients. Among periodontitis participants, 79% were EBV 
positive. Gingivitis and edentulous patients were 33% and 54% EBV positive, 
respectively. One-half of patients with periodontitis were HCMV positive. Conversely, 
gingivitis and edentulous patients were EBV free. Dentate patients were at an increased 
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risk for HCMV (OR=1.318), but not EBV. From these results, Sahin posited that his 
results suggested periodontitis lesions were the main source of salivary HCMV, as all 
other patient variables were controlled and the groups were equally matched 132. Sugano 
et al., collected stimulated whole saliva from subjects with periodontitis, defined as at 
least two sites with PD greater than 4. The saliva was then analyzed by PCR for P. 
gingivalis and EBV. 48.5% of patients were EBV positive, and P. gingivalis was 
signigicantly higher than in EBV negative salivary samples. No clinical measurements 
or data reflecting disease severity were reported 133. 
 Not all studies have reported high subgingival virus prevalence. Upon analysis of 
subgingival plaque samples, no HCMV was detected in chronic periodontitis, localized 
or generalized aggressive periodontitis, or healthy controls by Nibali et al., EBV was 
detected in 25% of localized aggressive periodontitis patients, but was undetected in 
chronic periodontitis patients. Furthermore, EBV detection was not statistically 
significantly different between any periodontitis group and healthy controls134. 
 Bilichodmath et al., reported the prevalence of herpesviruses in chronic and 
aggressive periodontitis patients in an Indian population. Subgingival plaque specimens 
were collected and processed by PCR. 26.32%, 100%, 15.7% and 78.9% of chronic 
periodontitis patients were HCMV, HSV-1, HSV-2 and EBV positive, respectively. 
Aggressive periodontitis patients were 7.14%, 57.14%, 0%, and 28.57% positive for 
HCMV, HSV-1, HSV-2 and EBV, respectively. The presence of HCMV, HSV-1, and 
EBV was statistically significant in chronic periodontitis patients, but was not significant 
among aggressive periodontitis patients. The presence of HSV-2 was not statistically 
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significant in either chronic or aggressive periodontitis patients 135. Imbronito et al., 
completed a similar study in Brazil. Because the disease definitions and viral detection 
methods were similar, comparison between the study results is possible. In addition to 
investigation of the prevalence of herpesviruses in chronic and aggressive periodontitis 
patients, herpesvirus prevalence in gingivitis and disease-free patients was also 
investigated. The patients were diagnosed using the same American Academy of 
Periodontology diagnostic criteria as applied in the Bilichodmath et al., study. Following 
nested PCR, Imbronito et al., reported that 50%, 40% and 46% of chronic periodontitis 
patients were HCMV, HSV-1, or EBV positive. Aggressive periodontitis patients were 
46.7%, 86.7% and 33.3% positive for HCMV, HSV-1, and EBV, respectively 136. The 
sample size per disease category was greater in the Imbronito study, with 30 participants 
per category, compared to less than 20 chronic or aggressive periodontitis patients in the 
Bilichodmath study.  Imbronito reported HCMV, HSV-1, and EBV in 56.7%, 20%, and 
0% of healthy patients, respectively, and 40%, 53%, and 20%, respectively, of gingivitis 
patients. As compared to chronic periodontitis and disease-free patients, the frequency of 
HSV-1 in aggressive periodontitis patients was significantly greater. The frequency of 
HCMV was not different between groups, while EBV-1 frequency was not significantly 
different between periodontitis/gingivitis groups and disease-free controls 137. Yapar et 
al., investigated HCMV and EBV in aggressive patients and reported 64.7% were 
HCMV positive, while 70.6% were EBV-1 positive. No disease-free controls were 
HCMV positive, and only 6.3% were EBV positive. All aggressive patients were treated 
with surgical therapy. However, viral frequency was evaluated only prior to therapy and 
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only clinical parameters were reported as indication of response to therapy 130. Grenier et 
al., demonstrated that viruses may be eliminated by non-surgical therapy, and evaluated 
GCF of healthy, gingivitis, and periodontitis patients by nested PCR amplification. 
HCMV prevalence was significantly higher in periodontitis as compared to periodontal 
health. Furthermore, as probing depth increased, HCMV incidence increased among 
periodontitis patients. Finally, of 48 study participants, 8 agreed to undergo non-surgical 
scaling periodontal therapy. Sites were evaluated for the presence of HCMV, EBV and 
HSV prior to and 6 week following therapy. 7, 1 and 4 of these patients were HCMV, 
EBV and HSV positive prior to treatment, respectively. At the time of re-evaluation, a 
single patient was HSV positive only 138. 
I.8 TOLL LIKE RECEPTOR 3 
 Toll-like receptors (TLRs) are pathogen recognition receptors that recognize 
multiple distinct pathogens associated molecular patterns (PAMPs). TLRs were first 
discovered in flies and later in humans. To date, 11 distinct TLRs have been discovered 
in humans. It has been established that TLRs play a critical role in the initiation of an 
innate immune response. Research suggests that they may play a role in the adaptive 
immune response as well. TLRs are type-1 membrane glycoproteins with PAMP-
recognizing extracellular leucine-rich repeats and cytoplasmic Toll/IL1 (TIR) receptor 
domain. The known TLRs are divided into 5 subfamilies based on amino acid sequence 
and genomic structure. TLR3 is unique among TLRs, with five exons, four of which 
encode its protein. All human TLR proteins except TLR3 proteins are encoded by no 
more than two exons. TLRs 3, 7, 8, 9 recognize viral and bacterial nucleic acid, while 
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TLRs 1, 2, 4, 5, 6,10 recognize PAMPs associated with bacteria, fungi and protozoa. 
Upon recognition of PAMPs, TLRs play a critical role in the initiation of an immune 
response 139. 
 TLR3 recognizes the PAMP viral double-stranded RNA is (dsRNA). dsRNA is 
produced during viral replication as either part of viral RNA genome or part of the 
replication cycle. Viral dsRNA, as well as endogenous dsRNA released from apoptotic 
cells activates TLR3. Polyriboinosinic:polyribocytidylic acid (polyI:C) is a synthetic 
dsRNA analogue and TLR3 ligand often used to study TLR3. Immune cells including 
dendritic cells, macrophages, natural killer cells, and mast cells express TLR3. Initially 
thought to be expressed exclusively intracellularly, mounting evidence indicates it is 
expressed extracellularly as well 140-142. 
 The macro structure of TLR3 is divided into three anatomic and functional sub-
structures defined by their spatial relationship to the membrane TLR3 traverses. The 
ectodomain contains multiple leucine-rich repeats (LRRs) and is responsible for ligand 
binding. 
  Among these LRRs, LRR 12 and LRR 20 are unique to TLR3. A total of 23 
LRRs are arranged into a polarized, heavily glycosylated solenoid (coil). This solenoid 
structure is bent into a horseshoe configuration with specialized domains capping the N- 
and C- terminal ends of the solenoid. The outer, convex surface of the horseshoe 
structure is positively charged. The inner, concave surface is negatively charged and 
hydrophobic. The hydrophobicity results from the inward orientation of the consensus 
leucine side chains of the LRRs. An extended parallel beta-sheet forms the concave 
 30 
 
surface. The beta-sheet is comprised of beta-strands contributed from the each of the 
eight residues of each LRR motif. A single disulfide bond stabilizes the hairpin look of 
the N-terminal motif. The C-terminal contains and internal alpha helix stabilized by 2 
disulfide bonds. The horseshoe confirmation is planar rather than twisted, as would be 
anticipated by constituent beta-sheet twist. The planarity is thought to result from 
irregularities in the loops, which connect beta strands of LRRs 8, 12, 14, 18, and 20. 
Short alpha helices and a large conserved loop at LRR 20 protrude from convex faces of 
the ectodomain. A large conserved loop formed by beta strands protrudes from LRR 12. 
The planarity of the ectodomain facilitates ligand binding and receptor signaling. The 
ectodomain is highly glycosylated, with carbohydrates apportioned on the convex, 
concave, and one of the two lateral surfaces. The opposite, non-glycosylated surface 
presents a large area for molecular interaction. A total of three points of contact are 
necessary between each TLR3 structure and dsRNA molecule for binding: the N-
terminal, C- terminal, and C-terminal dimerization site. An inverse relationship between 
TLR3/ligand binding in an environmental pH greater 6 exists. Beyond pH 6.5, TLR3 
will not bind its ligand. dsRNA must be at least 45 base pairs long to bind to its receptor 
and trigger an activation signal 143-145. 
 TLR3 binds dsRNA in dimeric pairs at three sites of interaction. Two sites bind 
dsRNA while one forms the dimer 146. As the length of the ligand increases, so does the 
number of dimers bound to the ligand. As Liu described, the TLR3 ectodomain does not 
undergo a conformational change once bound to dsRNA. Two TLR3 ectodomains at the 
C-terminal ends to form a dimer.  The glycan-free lateral surface of each horseshoe-
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shaped ectodomain interacts only with the ribose-phosphate backbone of the dsRNA 
ligand. Thus, TLR3 binds dsRNA independent of ligand base sequence 147. 
 Once the bound to its ligand and dimerized, the Toll-Il-1 receptor (TIR) is 
reoriented. This reorientation recruits the adapter molecule TIR domain-containing 
adapter inducing IFN-beat (TRIF). TRIF then connects to protein kinases TAK1, IKK 
and TBK/IKKeE. The subsequent activation of transcription factors IRF3, NF-kappaB, 
and AP-1 results in induction of IFN genes as well as hundreds of other cellular genes 
148, 149. 
 Yamashita observed TLR3 mediated signaling is not always preceded by gene 
induction, and signaling affects cellular properties independently of TRIF and MyD88 
adaptor proteins. The proto-oncoproteinc-Src is auto-phosphorylated by the TLR3-
dsRNA complex. Initially, this complex causes cell migration, proliferation and 
adhesion. However, lipid rafts contained in the plasma membrane sequester Src and 
inactivate it, causing inhibition of cell migration, proliferation and adhesion 150. 
 Alexopolou first observed that mammalian TLR3 recognizes dsRNA, and that 
the activation of the receptor induces NF-kB and the production of type I interferons 
(IFNs). In the novel study, polyinosine-polycytidylic acid (poly(I:C)) was used as a 
synthetic ligand for TLR3 151. dsRNA-induced up-regulation of co-stimulatory 
molecules was not entirely dependent on TLR2-Trif axis. dsRNA induced up-regulation 
of costimulatory molecules were entirely dependent on type I interferon receptor 
signaling. They found that genetic mutation in murine genes encoding Trif and TLR3 
had a strong inhibitory effect on dsRNA -induced synthesis of TNF and type I 
 32 
 
 interferon 152. Matsukura showed that TLR3 was expressed inside airway epithelial cells 
and up-regulates expression of inflammatory cytokines and chemokines through the 
TLR3-NF-kB and TLR3-IRF3 signaling when stimulated by poly(I:C) 153. Matsumoto et 
al., observed poly(I:C) induction of NF-κB and IFN-β. The recognition of dsRNA by 
TLR3 was highly specific, discriminating between the presence and absence of a 
hydroxyl group bound to the 2′ carbon in beta-d-ribose 154. Duffy et al., created a 
monoclonal antibody (mAb) that recognizes the extracellular domain of human TLR3 in 
a conformation-dependent manner. Application of this mAb to poly(I:C) stimulated 
human lung epithelial cells results in down-regulation of IL-6, IL-8, MCP-1, RANTES, 
and IP-10 production, as well as NF-B, IRF-3/ISRE, and p38 MAPK 155.  
 A mAb recognizing the extracellular domain of murine TLR3 was developed by 
Bunting et al., and applied to a murine model in vivo. This anti-TLR3 antibody resulted 
in concentration-dependent inhibition of poly(I:C)-induced NF-B activation and 
chemokine generation. This finding further validated previously described TLR3-elicited 
inflammatory pathways and suggested either that anti-TLR3 antibody is transported 
across the plasma membrane to endosomal TLR3, or a role for extracellular plasma 
membrane-associated TLR3 156. TLR3 has been observed by Kleinman et al., to bind 
small interfering RNA (siRNA) as well. In a murine model, 21-nucleotide siRNA caused 
phosphorylation of cell surface TLR3 on lymphatic endothelial cells as well as blood 
endothelial cells and induces apoptosis. Thus, TLR3 activation may jointly suppress 
blood and lymphatic neovascularization 157. Further study of murine TLR3 stimulation 
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with siRNA induced retinal degeneration, and TLR3 is expressed on the cell surface of 
retinal pigment epithelial cells 158. 
I.9 ANALYSIS OF SERUM AND SALIVA 
 Blood has long been used in the diagnosis and monitoring of pathogenesis, 
whether the result of an exogenous infection or autogenous dysregulation. The formed 
elements of blood, erythrocytes, leukocytes, thrombocytes, as well as plasma and 
clotting factors, exist in ranges considered normal.  When collected blood is allowed to 
clot, serum forms a distinct layer, separate from the formed elements and without 
clotting factors, or fibrinogens. Serum does contain antibodies, antigens, hormones, 
electrolytes, and if present, pathogenic species, drugs, and drug metabolites. Serologic 
analysis has been used in the investigation of periodontal disease as well, to further 
elucidate viral, immunologic, bacteriologic, and inflammatory mediatory profiles in the 
progression and treatment of the disease 128, 159, 160. 
 Saliva is a diagnostic body fluid that may be non-invasively collected. It is used 
presently to diagnose disease, and in the investigation of malignant neoplasia, 
autoimmune disorders and hormonal analysis 161. Salivary testing offers great sensitivity 
and specificity in the diagnosis of HIV, HHV, CMV, EBV and hepatitis C virus 162, and 
characteristic alterations in salivary chloride and sodium concentrations may be 
diagnostic cystic fibrosis 163. Saliva and GCF have been extensively studied in both SS 
and periodontal disease. Kinney et al., and Sexton et al., reported described a significant 
correlation of salivary and GCF biomarkers including MMP-8, MMP-9, osteoprotegerin, 
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C-reactive protein, IL-1beta, and MIP-1alpha, with clinical periodontal parameters. Both 
posited salivary analysis as a sensitive measure of periodontal disease progression 164, 165. 
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CHAPTER II 
COMPARISON OF SALIVARY AND SERUM LEVELS OF SOLUBLE TOLL-
LIKE RECEPTOR 3 (TLR3) IN PATIENTS WITH SJÖGREN’S SYNDROME 
(SS) COMPARED TO AGE- AND SEX-MATCHED CONTROLS 
 
II.1 SYNOPSIS 
II.1.1 Background 
 This cross-sectional study examined potential differences in concentration of 
Toll-like receptor 3 (TLR3) in serum and citric acid-stimulated saliva from patients with 
Sjögren’s Syndrome (SS) and healthy age-, sex-, and periodontal disease matched 
control patients.   
II.1.2 Methods 
Salivation was stimulated with 5.0 ml of 2% citric acid, and whole saliva samples 
were collected. Full-mouth clinical periodontal measurements were recorded from 21 SS 
patients and 22 unaffected control patients. Saliva and plasma TLR3 concentrations were 
determined by enzyme-linked immunoassays (ELISA). Data were tested statistically as 
appropriate to the data distribution. 
II.1.3 Results 
No difference in age, body mass index (BMI), salivary TLR3 concentrations, or 
clinical periodontal measurements were evident between groups. Salivary flow rates 
were significantly lower (p<0.001) whereas plaque % were significantly higher 
(p=0.048) in SS patients. Mean saliva and serum TLR3 levels were 0.183 ng/ml and 
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0.219 ng/ml, respectively, in SS patients. Mean saliva and serum TLR3 levels were 
0.299 and 0.188 ng/ml, respectively, in healthy patients. There was no significant 
difference between serum or saliva in SS patients or healthy control patients. 
II.1.4 Conclusion 
 The present findings do not support a hypothesis that a hyperinflammatory 
systemic state, as seen in treated SS patients, can independently raise serum or saliva 
TLR3 concentration in the absence of periodontal disease.  This is the first report of 
TLR3 detection in human serum and saliva by ELISA.  
II.2 INTRODUCTION 
 Sjögren’s Syndrome (SS) is a chronic, systemic autoimmune disorder. The 
course of the disease destroys salivary and lacrimal glands, often causing xerostomia and 
xeropthalmia. Pulmonary, hepatic, renal, and neurologic extraglandular involvement 
may result as well. B-lymphocyte hyper-reactivity, autoantibody production and T-cell 
lymphocytic infiltration to exocrine glands, and commonly, other organs, are 
characteristic of SS pathosis, though the precise etiology, or etiologies, remains 
unknown1. 
Though the cause of the cellular activation and chronic inflammatory response 
that targets epithelial cells in SS has not been determined, a viral pathogenesis has long 
been suspected. Multiple studies have observed a correlation of viruses and SS. Elevated 
Epstein-Barr virus (EBV) levels in the blood, saliva, and salivary gland tissue of SS 
patients as compared to non-diseased controls are widely reported 104,105,106,107. Human 
cytomegalovirus (HCMV), hepatitis C virus, coxsackie virus, and human T 
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lymphotropic virus type I, are among many viruses that have been investigated as 
causative and contributory factors as well166-171. Viral ligands activate Toll-like receptors 
(TLRs) 3, 7, 8, and 9 resulting in exocrine gland alteration. Once activated, TLR 
pathways culminate in type 1 interferon (IFN-1) activation and chemokine production 
characteristic of the salivary gland immune response in SS 172.  
 When bound to double-stranded RNA (dsRNA), TLR3 initiates an innate 
immune response139, and may facilitate an adaptive immune response as well. dsRNA is 
a structure common to many viruses, and may be expressed during the replication of 
non-dsRNA viruses. Mast cells, macrophages, natural killer cells, B, Th1, Th2 and 
myeloid dendritic cells (DCs) all express TLR3.173 Initially thought to be expressed 
exclusively intracellularly, it is likely expressed extracellularly as well 140, 141, 142. 
Ligation induces IFN genes and production of numerous inflammatory cytokines and 
chemokines, including IFN-α, IFN-β, TNF-α, IL-6, IL-12, IP-10, and RANTES174,148,148. 
Like SS, a viral pathogenesis for periodontal disease has been investigated. EBV, 
HCMV, and herpes simplex virus (HSV), as well as other common viruses have been 
implicated in the pathosis of periodontal disease. Virus-positive samples from 
subgingival plaque samples, gingival crevicular fluid, tissue biopsies, as well as serum 
and saliva samples have been collected and correlated with periodontal disease severity 
and frequency. EBV presence in periodontal lesions was positively correlated to P. 
gingivalis frequency 133. Periodontal lesions may be the primary origin of salivary 
HCMV, as well as a significant source of salivary EBV 132. Viral pathogens have been 
detected in diseased periodontal tissue as well. EBV DNA has been observed in the 
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interproximal papilla126, and junctional and sulcular epithelial cells of diseased 
individuals127. 
Though they may share a viral etiology, the relationship, if any exists, between 
SS and periodontal disease is unclear. Antoniazzi et al., and Najera et al., observed 
periodontal parameters such as probing depth, gingival and plaque index, clinical 
attachment loss, and bleeding on probing were significantly worse among SS patients as 
compared to SS-free patients 81,82. Conversely, Kuru et al., reported that the occurrence, 
severity and extent of periodontal disease as quantified by clinical parameters were not 
significantly different between pSS, sSS and SS-free patients 84. Schiødt et al., as well as 
others, concluded that pSS is not associated with increased risk of periodontal disease 85-
88,92. 
Blood has long been used in the diagnosis and monitoring of pathosis.  When 
collected blood is allowed to clot, serum forms a distinct layer, containing antibodies, 
antigens, hormones, electrolytes, and if present, pathogenic species, drugs, and drug 
metabolites. Saliva contains many of the same elements as serum, and can also be used 
to diagnose and monitor pathosis 161. Unlike serum, saliva can be non-invasively 
collected. 
 There are no studies to date that have investigated the presence and quantity of 
TLR3 in the saliva and serum of periodontally healthy patients with SS. Our hypothesis 
is that salva and serum levels of TLR3 are increased in SS patients due to up-regulation 
by stimuli generated from receptor crosstalk involved in the signaling cascades of 
induction and progression of SS. 
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II.3 MATERIALS AND METHODS 
II.3.1 Patient Selection 
 Forty-three subjects were included in the study.  The study protocol was 
approved by the Texas A&M Health Science Center Institutional Review Board, and 
conducted in full compliance with ethical principles, including the 2000 revision 
Helsinki Declaration of 1975. Twenty-one non-smoker, SS-positive patients and twenty-
two, non-smoking, age and sex-matched control patients were recruited. SS patients 
were recruited from October 2012 to August 2013 from the Stomatology and Salivary 
Dysfunction Clinic at TAMU Baylor College of Dentistry (TAMUBCD). Control 
patients were recruited from the faculty and staff of Texas A&M University-Baylor 
College of Dentistry. A positive SS diagnosis was made by satisfying the American-
European Consensus Classification Criteria 38. Prior to salivary and venous blood 
sampling, and clinical periodontal examination, the study protocol was explained, and 
written informed consent, medical and dental histories were obtained. No less than 16 
teeth including at least 2 molars, were present in each patient. Exclusion criteria were 
diabetes mellitus, hepatitis, malignancies, pregnancy and/or lactation, less than 18 years 
old, or periodontal therapy within the previous 6 months. The clinical case definitions 
proposed by the Centers for Disease Control working group for use in population based 
surveillance of periodontitis were used for periodontal disease assessment 175. Patients 
with neither more than 1 interproximal site with clinical attachment loss of at least 3 
mm, nor more than 1 interproximal site with probing depth of at least 4 mm, were 
considered periodontitis-free. Following SS patient data collection, age and sex-matched 
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control patients were recruited and appropriately excluded according to the 
aforementioned criteria. This effort was made to exclude or minimize any effect 
periodontal disease may have on serum and salivary levels of TLR3. 
II.3.2 Saliva Collection 
 Stimulated saliva was collected as described by Navazesh et al. 176. Patients were 
instructed to brush, floss, rinse with water, and fast for two hours prior to saliva 
collection. Immediately before collection, patients rinsed with 10 ml of sterile deionized 
water for 1 minute and expectorated. A five second swish of 5 ml of 2% citric acid 
followed to stimulate salivary flow. After 1 minute, the patient again expectorated to 
void any accumulated secretions. Expectorated whole saliva was then collected on ice in 
sterile pre-weighed 50.0 ml polypropylene tubes until 5.0 ml was collected or 20 minutes 
had elapsed. The collection period was timed to allow for salivary flow rate calculation, 
and the determination of the captured sample weight. Collected saliva was immediately 
centrifuged (800g) for 10 minutes at 4°C, then aliquoted into 500 µl portions. These 
portions were then frozen and stored at -80°C until all study samples were collected. All 
portions were thawed immediately prior to assay. 
II.3.3 Serum Collection 
 10 ml of venous blood was collected by standard venipuncture with vacutainers A 
from the antecubital fossa or superficial veins of the hand. Immediately after collection, 
the vacutainer was inverted 5 times and then left undisturbed for 1 hour per 
manufacturer’s recommendation. 12,000 rpm centrifugation for 10 minutes separated 
                                                 
A BD Biosciences, North America 
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serum from blood. The serum was then frozen and stored at -80°C until all study 
samples were collected. All samples were thawed immediately prior to assay. 
II.3.4 Periodontal Examination 
 Following saliva and serum collection, clinical periodontal parameters including 
probing depth (PD), clinical attachment level (CAL), and bleeding on probing (BOP) 
were recorded with an UNC15 probe B.  BOP was positive if it occurred within 30 
seconds following probing. CAL was calculated as the distance between the base of a 
probable pocket and the cement-enamel junction. A Nabors probe and bi-digital 
manipulation determined the degree of furcation involvement (Glickman classification) 
and mobility (Miller classification) if present, respectively. A disclosing agent C was 
applied per manufacturer’s recommendation, and plaque was recorded dichotomously as 
present or absent at six sites per tooth, including mesial-, mid-, and distal- labial and 
lingual surfaces. Two examiners (HP, JB), calibrated prior to and three months after 
following the study initiation, recorded all measurements. Demographic and periodontal 
measurements were reported for all patients in the study (n=21 SS, n=22 control).   
II.3.5 Measurement of TLR3 in Serum and Saliva 
 Two samples, one test and one control, used for calibration purposes were not 
included in ELISA analysis. The remaining 20 test samples and 20 randomly picked 
(coin flip) control samples were selected for analysis with TLR3 enzyme-linked 
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immunosorbent assay (ELISA) kits D following the manufacturer’s protocol. The average 
optical density (OD) of each undiluted saliva and serum sample was compared to the 
assay standard curve concentrations to determine TLR3 concentration. A linear equation 
derived from the standard curve and measured OD values was used to derive TLR3 
concentration in samples with OD beyond the maximum detectable range. The lower and 
upper detection thresholds for TLR3 assay were 0.016 ng/ml and 10.0 ng/ml, 
respectively.  
II.3.6 Statistical Analysis 
 Shapiro-Wilk normality tests were performed on all numerical variables with the 
null hypothesis that the variable in question was normal versus the alterative that the 
variable was not normal. For variables that were normal, a t-test was performed between 
the control group and the SS group. For variables that were not normal, Mann-Whitney 
was used, and to settle disputes caused by ties in Mann-Whitney, jittering was used and 
repeated (Monte-Carlo) with 10,000 permutations. The p-value was averaged over the 
10,000 permutations, creating a simulated p-value, and reported. Correlation coefficients 
were found using Pearson’s correlation coefficient between variables, and correlation 
coefficients greater than 0.6 were considered to be noteworthy. Finally, for the binary 
data if the patient visited the dentist in the past 6 months (1 = Yes and 0 = No), the 
Fisher’s Exact Test was used because this data was structured as a 2x2 contingency 
table.  
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 The number of patients taking an individual medication was counted and 
summed according to the therapeutic category the medication belonged to (e.g. 
antihypertensives, psychologics, biologics, etc.). A percent difference was calculated as:  
(number of SS patients taking drug – number control patients taking drug) 
(number of SS patients taking drug). 
 The distribution of the number of drugs taken by patients was tested for 
normality using the Shapiro-Wilk statistic, which indicated that the distribution was in 
fact not normal. Therefore, the total number of drugs used by the SS group and control 
group was analyzed using a Mann-Whitney test to see if there was a significant 
difference.  
 Serum and saliva were analyzed for TLR3 using a Mann-Whitney test for 
analysis. Twenty patients were used for each group because of the cost of measuring 
TLR3. Two patients from the control group were subsequently randomly discarded and 
one patient from the test group was also discarded. All tests were performed at alpha = 
0.05.  All statistical tests were completed with SPSS (IBM).   
II.4 RESULTS 
II.4.1 Clinical Results 
 There were no significant differences between the examiners for measured 
clinical variables (Table 1, Figure 1). Table 2 reports the mean and median values 
obtained for all clinical variables. SS and control groups did not differ significantly 
(p>0.05) in age, BMI, PD, CAL, BOP, mobility, PD >= 4 mm, furcation involvement, or 
dental care, with both groups reporting at least semiannual dental care. Conversely, 
 44 
 
salivary mass and salivary flow were significantly lower (p<0.001), and plaque 
percentage significantly higher (p<0.049) in SS group as compared to controls. 
As compared to the control group, a greater number of SS group patients took 
drugs in 11 of 14 drug categories (Table 3). A greater number of control group patients 
took drugs belonging to antihypertensive, antiplatelet and allergy medications. However, 
the amount of medication to treat allergies, hypertension, and hyperlipidemia were not 
significantly different between groups. SS patients took significantly more medications 
to treat hyperlipidemia, psychological conditions, xerostomia, pain, gastro-esophageal 
reflux disease, insomnia, thyroid dysregulation, hormone replacement therapy, and anti-
malarial agents. On average, patients belonging to SS group took 6.61 drugs as 
compared to 2.36 drugs taken by control patients. 
Correlations were calculated. Correlations with r>.6 were determined to be 
relevant. Relevant correlations include Flow with Saliva Mass (r=.863), Flow with 
Collection Time (r=-.759), Average PD with Average CAL (r=.604), PD > 5 mm with 
Collection Time (r=.655), and number of Grade 1 Furcation with Grade 2 Furcation 
involvement (r=.617).  The variables that showed significance with the appropriate 
hypothesis testing (α=.05) were Salivary Mass (p < .001), Salivary Flow (p < .001), and 
plaque index (p = .049). Age showed moderate significance between the two groups 
(p=.085). The 3:18 ratio of men-women in the SS group of the study reflected the 
population proportion of 1:9 accurately, with no significant difference between the study 
and the true population proportion. A z-proportion test result of p=.735 confirmed this 
finding. 
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II.4.2 Saliva and Serum TLR3 Concentration 
 There was no statistically significant difference in saliva or serum TLR3 levels 
between patient groups (p = 0.465 and 0.556, respectively) (Table 4). 
 A post-hoc power analysis was performed using the observed ELISA results. The 
observed effect sizes for serum and saliva were 0.11 ng/ml and 0.16 ng/ml, respectively. 
II. 5 DISCUSSION 
 With the exception of the percentage of plaque present, the clinical periodontal 
parameters reported in this study were not significantly different between SS and control 
groups. PD, CAL, BOP, mobility, PD >= 4 mm, furcation involvement, and dental care, 
were all similar. The periodontal disease status of SS patients as compared to disease 
free controls was grossly equivalent. This finding is in agreement with the observations 
of multiple authors 84-86, 88. Kuru concluded that among pSS, sSS and SS-free patients, 
PI, GI, BOP, PD, CAL, and occurrence, severity and extent of periodontal lesions were 
not significantly different 84. Boutsi et al., found no difference in the clinical periodontal 
parameters between pSS/sSS patients and healthy controls 88. With few exceptions, 
Jorkjend reported no statistically significant difference between the periodontal status of 
SS and healthy controls, concluding that SS patients do not have an increased risk for 
developing periodontitis 90. 
 However, not all studies have produced similar observations. Najera et al., 
reported significantly higher PI, increased alveolar bone loss, CAL and cement-enamel 
junction to-bone crest loss among SS patients. An odds ratio analysis of this data placed 
SS patients at a 2.2 times higher risk of periodontal disease than SS-free individuals 82. 
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In accord with Najera, Antoniazzi et al., posited that SS patients had significantly higher 
PI, GI, PD, CAL, and BOP 81.  
 The single significantly different clinical parameter between SS and control 
groups was plaque, with 25.6% and 19.5% of surfaces plaque-positive, respectively. 
Whether a 6% difference is clinically significant is subject to debate. Furthermore, 
because the method of plaque recording made no quantification of the amount of plaque, 
but only presence or absence, the biologic burden presented to the periodontium may not 
be accurately reflected by this metric. 
 The mass of collected saliva and salivary flow were significantly different 
between groups as well, with SS patients having significantly lower mass and flow. This 
finding of relative hyposalivation, and the oft-accompanying symptom xerostomia is 
well-documented 6, 62. Decreased salivary output might explain the observed significant 
difference in plaque. 
 By the very nature of the study design, which selected SS patients who were 
properly diagnosed and treated, poorly managed SS patients were likely excluded. 
Because it is unethical to demand patients cease successful therapy, or discontinue use of 
any medication for the purpose of an investigation, it is possible that the continued 
pharmacologic management of SS by patients may alter TLR3 expression. SS patients 
took significantly more medications to treat hyperlipidemia, psychological conditions, 
xerostomia, pain, gastro-esophageal reflux disease, insomnia, and thyroid dysregulation, 
as well as medications for hormone replacement therapy and anti-malarial agents.  
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Because SS disproportionately afflicts peri- and post-menopausal females, many women 
suffering from SS may receive hormone replacement therapy (HRT). One-half of SS 
patients in this study reported HRT. The expression of TLR3 mRNA is known to 
fluctuate during the menstrual cycle, and may be correlated to hormonal fluctuation. 
Analysis of endometrial biopsies obtained throughout the human menstrual cycle show 
significant variance in TLR3 mRNA expression. TLR3 mRNA expression is 
significantly higher in the early proliferative phase than the late proliferative phase, and 
is significantly higher in the late secretary phase than the late proliferative and early 
secretary phase 177. Indeed, two case reports of SS following initiation of estrogen HRT 
have been reported 178. Furthermore, Jones et al., investigated progesterone modulation 
of murine bone marrow-derived dendritic cell cytokine production (IL-6 and IL-12) and 
costimulatory molecule expression (CD40, CD80, and CD86) induced by TLR3. 
Progesterone was found to downregulate TLR3 -induced IL-6 production via the 
glucocorticoid receptor, and downregulated IL-12p40 production via either the 
glucocorticioid receptor or progesterone receptor. Progesterone also significantly 
inhibited TLR3-CD40 expression in bone marrow-derived DCs 179. Though not 
definitive, much evidence suggests hormonal levels impact TLR3 expression. 
 Nine of 20 SS patients reported the use of the anti-malarial drug 
hydroxychloroquine. Anti-malarial agents are known to alter immune regulation and 
response, and are used therapeutically in multiple autoimmune disorders. Chloroquine 
and quinacrine efficiently inhibited production of inflammatory cytokines in pDC and 
PBMCs incubated with the immune complexes of sera from systemic lupus 
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erythematous patients. Chloroquine and quinacrine had inhibitory effects on TLR3 
signaling when these receptors were stimulated with nucleic acids. Poly(I:C) was unable 
to trigger activation of TLR3 due to changes in conformation of nucleic acids following 
interaction with chlorquine with nucleic acids. Although conducted in vitro, this 
provides evidence of TLR3 alteration when anti-malarial drugs are present 180. 
 To date, the authors are unaware of any study that analyzed human serum or 
saliva for TLR3 by ELISA. Although no significant difference in the serum or saliva 
TLR3 levels between SS and healthy controls was observed, it was previously unknown 
whether TLR3 could be detected. Therefore, the data generated may serve to establish 
baseline or normative values. Although TLR3 expression should correlate with the level 
of viral dsRNA, and thus viral infection, it is an indirect indicator. 
 A post-hoc power analysis was performed using the observed ELISA results. 
Because this study was novel, an a priori power analysis could not be conducted, and a 
power analysis for a study of TLR4 conducted in parallel was used. The observed effect 
sizes for serum and saliva TLR3 were 0.11 ng/ml and 0.16 ng/ml, respectively. 
Hypothetically, the effect sizes for serum and saliva would be 0.232 ng/ml and 0.314, 
respectively, when achieving a power of 0.8. This would necessitate 294 and 160 age- 
and sex- matched study participants for serum and saliva, respectively. As such, the 
findings of this study should not be interpreted as evidence of an absence of viral 
pathosis in SS. Rather, additional investigation with a greater sample size is necessary. 
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CHAPTER III  
CONCLUSION 
 
 This is the first study to detect, and quantify, TLR3 by ELISA in human serum 
and saliva samples. The values recorded in this study may be applied to establishing 
normative TLR3 values. The present study observed that SS patients had comparable 
periodontal status when compared to age- and sex-matched controls as quantified by 
clinical parameters. SS patients demonstrated significantly greater plaque percentage and 
significantly lower salivary flow rate. Serum and saliva levels of TLR3 did not differ 
significantly between SS and control groups. 
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APPENDIX A  
FIGURES 
 
 
FIGURE 1: LIMITS OF EXAMINER AGREEMENT 
   
Bland-Altman Plots. The dotted lines in each plot is the 95% confidence interval margins around the bias. 
The buccal and palatal plots show one point outside the bands. The total plot shows the combination of the 
palatal and buccal plots.  
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APPENDIX B  
TABLES 
 
 
TABLE 1: CALIBRATION STATISTICS 
 
 Buccal Palatal Total 
Percent Agreement  65.7 54.3 60.0 
T-test p-value .459 .122 .496 
ICC .628 .491 .558 
T-test p-value (Bias)  .229    (0.047) .519     (-0.114) .750    (-0.033) 
Both raters were similar. The total percent agreement was above 60%, and the total t-test 
for the raw difference between both raters was not significant (p-value = .496). 
Additionally, the t-test for bias was insignificant (p-value = .75). 
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TABLE 2: PATIENT DEMOGRAPHICS, SALIVA MEASUREMENTS, AND 
PERIODONTAL MEASUREMENTS 
 
 SS Patients 
n = 21 
Median (IQR)* 
Control Patients 
n = 22 
Median (IQR)* 
p-value 
Age (years)* 59.3 (12.07) 52.6 (12.99) 0.085 
Saliva Mass (g)* 3.31 (1.48) 4.99 (1.37) <0.001 
Salivary Flow (g/min) 0.30 (0.19) 0.89 (0.57) <0.001 
Body Mass Index* 28.6 (7.24) 29.9 (7.53) 0.549 
Average Probing Depth 
(mm)* 
2.27 (0.42) 2.33 (0.25) 0.552 
Average Clinical 
Attachment Loss (CAL) 
(mm)* 
2.58 (.58) 2.50 (0.41) 0.569 
Bleeding on Probing  1.00 (8.00) 0.50 (2.00) 0.225 
Plaque % 25.6 (35.90) 19.5 (10.00) 0.049 
Class 1 Mobility (# teeth) 0.00 (0.00) 0.00 (0.00) 0.547 
Class 2 and 3 Mobility (# 
teeth) 
N/A N/A N/A 
Probing depth ≥4mm (# 
teeth) 
0 (4.00) 0 (1.00) 0.568 
Probing depth ≥5mm (# 
teeth) 
0 (0.00) 0 (0.00) 0.423 
Grade 1 Furcations (# 
teeth) 
1.00 (2.00) 0.00 (1.75) 0.397 
Grade 2 Furcations (# 
teeth) 
0.00 (0.00) 0.00 (0.00) 0.408 
Grade 3 Furcations (# 
teeth) 
N/A N/A N/A 
Dental visits in last >2 
times per year (% of group 
who did)** 
67 54 0.132 
The single star (*) indicates a variable that was determined normal by Shapiro-Wilk statistic. For each 
normal variable the mean and standard deviations were reported. Additionally, a t-test was performed, and 
its associated p-value was reported.  For those not marked with a single star (*) or a double star (**), the 
median and interquartile range (IQR) was reported, as well as the p-value from the Mann-Whitney test. 
Finally, the final row (designated as “**”), the percent of patients who did visit the dentist within 6 months 
and the p-value from Fisher’s exact test was reported. 
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TABLE 3: MEDICATION INFORMATION FOR CONTROL AND SS GROUPS 
 
Medication 
# Medications 
in SS patients 
# Medications 
in Control 
Patients 
Percent 
Difference 
(%) 
ANTIHYPERTENSIVES  8 15 
-87.5 
 Beta-blockers 2 4 
 Diuretics 1 6 
 Ca++ blockers 4 2 
 Angiotensin 2 inhibitors 1 3 
ANTI-PLATELET 3 5 
-66.7  Salicylic Acid 3 3 
 Clopidrigel 0 2 
ANTI-HYPERLIPIDEMICS 6 4 33.3 
GASTROESOPHAGEAL REFLUX DISEASE 
(GERD) 
11 5 
54.5  Proton Pump Inhibitors 9 5 
 Antacids 2 0 
PYSCHOLOGIC 10 5 
50.0 
 Selective serotonin reuptake 
inhibitors 
5 2 
 Norepinephrine reuptake 
inhibitors 
1 1 
 Lithium 2 1 
 Tricyclic anti-depressants 1 1 
 Atypical anti-psychotic 1 0 
ANALGESICS 28 11 60.7 
 Nsaids 8 4 
 Barbituates 1 0 
 Opiods 5 1 
 Systemic Steroids 1 0 
 Muscle Relaxers 6 3 
 Anti-migraine 1 1 
 Gabapentin 3 1 
 Cox-2 Inhibitors 0 1 
 Pregabalin 4 0 
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TABLE 3: CONTINUED 
 
 
Medication 
# Medications 
in SS patients 
# Medications 
in Control 
Patients 
Percent 
Difference 
(%) 
    
ALLERGY 5 7 
-40.0 
 Leukotriene receptor antagonist 1 1 
 Histamine receptor antagonist 0 2 
 Nasal corticosteroid 3 2 
 Inhaled corticosteroid  1 1 
 Ophthalmic antihistamine 0 1 
HORMONE REPLACEMENT THERAPY 10 1 
90.0  Estrogen receptor agonist 9 1 
 Progesterone receptor agonist 1 0 
HYPOTHYROID 7 2 71.4 
SIALOGOGUES 18 0 100.0 
INSOMNIA 10 0 
100.0  Benzodiazepines 6 0 
 Zolpiderm 4 0 
ANTI-MALARIALS 9 0 100.0 
MISCELLANEOUS 6 2 
66.7 
 Ophthalmic drops for dry eye  4 1 
 Bladder-selective Alpha-1 
  antagonists 
0 1 
 Bisphosphonates 2 0 
BIOLOGICS  1 0 100.0 
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TABLE 3: CONTINUED 
This table shows the aggregate number patients taking drugs and types of drugs. The bolded numbers along 
with the bolded and capitalized category shows the total number of patients taking the drugs listed per the 
specific test group status.  
 
 
TABLE 4: SALIVARY AND SERUM TLR3 LEVELS FOR SS AND CONTROL 
GROUPS AND ASSOCIATED P-VALUES 
 
 SS Patients 
n = 20 
Median (IQR) 
Control Patients 
n = 20 
Median (IQR) 
p-value 
Salivary TLR3 (ng/mL) 0.183 (.440) 0.299 (.758) 0.465 
Serum TLR3 (mg/mL) 0.219 (.426) 0.188 (.387) 0.556 
 
 
Total # medications 117 57 51.3 
Average # medications/pt 6.61 2.36 64.3 
